Inhibition of CD95 ligand-mediated inflammation

Transplant Proc. 2000 Nov;32(7):2038-9. doi: 10.1016/s0041-1345(00)01548-7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Cell Division / drug effects
  • Cell Division / immunology
  • Diabetes Mellitus, Experimental / surgery*
  • Fas Ligand Protein
  • Glycine / analogs & derivatives
  • Glycine / pharmacology
  • Hydroxamic Acids / pharmacology
  • Inflammation / prevention & control*
  • Interleukin-10 / genetics
  • Interleukin-10 / immunology
  • Islets of Langerhans Transplantation / immunology*
  • Liver Neoplasms, Experimental / pathology*
  • Male
  • Membrane Glycoproteins / immunology*
  • Metalloendopeptidases / antagonists & inhibitors
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C3H
  • Mice, Inbred DBA
  • Rats
  • Rats, Sprague-Dawley
  • Recombinant Proteins / immunology
  • Transfection
  • Transplantation, Heterologous / immunology*
  • Tumor Cells, Cultured
  • fas Receptor / genetics
  • fas Receptor / immunology

Substances

  • Antineoplastic Agents
  • Fas Ligand Protein
  • Fasl protein, mouse
  • Faslg protein, rat
  • Hydroxamic Acids
  • KB R7785
  • Membrane Glycoproteins
  • Recombinant Proteins
  • fas Receptor
  • Interleukin-10
  • Metalloendopeptidases
  • Glycine